SVA Plumb Wealth Management LLC cut its position in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 4.7% during the 1st quarter, Holdings Channel reports. The firm owned 39,274 shares of the medical research company’s stock after selling 1,950 shares during the quarter. SVA Plumb Wealth Management LLC’s holdings in EXACT Sciences were worth $3,402,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in EXAS. Man Group plc acquired a new stake in shares of EXACT Sciences during the 3rd quarter worth approximately $728,000. Vanguard Group Inc boosted its position in shares of EXACT Sciences by 2.6% during the 3rd quarter. Vanguard Group Inc now owns 10,498,087 shares of the medical research company’s stock worth $828,509,000 after acquiring an additional 261,239 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of EXACT Sciences during the 4th quarter worth approximately $286,000. Meeder Asset Management Inc. boosted its position in shares of EXACT Sciences by 602.9% during the 4th quarter. Meeder Asset Management Inc. now owns 2,910 shares of the medical research company’s stock worth $184,000 after acquiring an additional 2,496 shares in the last quarter. Finally, R.H. Dinel Investment Counsel Inc. acquired a new stake in shares of EXACT Sciences during the 4th quarter worth approximately $4,095,000. Institutional investors and hedge funds own 87.63% of the company’s stock.
In related news, insider Kevin T. Conroy sold 9,169 shares of EXACT Sciences stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $95.07, for a total transaction of $871,696.83. Following the completion of the transaction, the insider now owns 923,961 shares of the company’s stock, valued at $87,840,972.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Mark Stenhouse sold 11,192 shares of EXACT Sciences stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $92.54, for a total transaction of $1,035,707.68. Following the transaction, the insider now directly owns 25,500 shares of the company’s stock, valued at approximately $2,359,770. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,201 shares of company stock worth $5,543,493. 3.20% of the stock is owned by company insiders.
EXAS has been the topic of several analyst reports. Zacks Investment Research lowered shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, February 13th. UBS Group increased their price target on shares of EXACT Sciences from $109.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, April 16th. Robert W. Baird increased their price target on shares of EXACT Sciences from $90.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, February 21st. BTIG Research increased their price target on shares of EXACT Sciences to $110.00 and gave the stock a “positive” rating in a research report on Friday, February 22nd. Finally, Goldman Sachs Group upgraded shares of EXACT Sciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $85.00 to $120.00 in a research report on Tuesday, February 26th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $108.45.
Shares of NASDAQ:EXAS traded up $2.71 during mid-day trading on Wednesday, reaching $94.71. 215,977 shares of the company’s stock were exchanged, compared to its average volume of 1,832,410. The firm has a market cap of $11.56 billion, a PE ratio of -69.64 and a beta of 1.84. The company has a debt-to-equity ratio of 1.02, a quick ratio of 8.13 and a current ratio of 8.39. EXACT Sciences Co. has a twelve month low of $47.78 and a twelve month high of $105.28.
EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Tuesday, April 30th. The medical research company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.01). The business had revenue of $162.00 million for the quarter, compared to analyst estimates of $153.07 million. EXACT Sciences had a negative return on equity of 28.83% and a negative net margin of 41.58%. EXACT Sciences’s revenue for the quarter was up 79.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.33) EPS. Sell-side analysts forecast that EXACT Sciences Co. will post -2.13 EPS for the current year.
WARNING: “SVA Plumb Wealth Management LLC Has $3.40 Million Position in EXACT Sciences Co. (EXAS)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2019/05/15/sva-plumb-wealth-management-llc-has-3-40-million-position-in-exact-sciences-co-exas.html.
EXACT Sciences Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Recommended Story: Trading Ex-Dividend Strategy
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.